FDA OKs In­grez­za for treat­ing chorea as­so­ci­at­ed with Hunt­ing­ton’s; Abi­vax inks agree­ment for up to $163M in debt fi­nanc­ing

The FDA on Fri­day ap­proved Neu­ro­crine Bio­sciences’ In­grez­za to treat adults with chorea as­so­ci­at­ed with Hunt­ing­ton’s dis­ease.

In­grez­za, al­so known as val­be­nazine, was first ap­proved by the FDA in 2017 to treat tar­dive dysk­i­ne­sia, which can cause un­con­trol­lable jerk­ing move­ments in the face and body. Chorea is al­so a con­di­tion that can gen­er­ate ran­dom and sud­den jerk­ing move­ments in the body and can oc­cur in pa­tients with Hunt­ing­ton’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER